Lantheus Holdings, Inc.

LNTH Healthcare Drug Manufacturers Specialty & Generic

Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.

Revenue
+1.54%
EPS
−16.4%
Free cash flow
+7.71%
Total debt
+0.52%

Quarter to September 2026, against a year earlier

100.65 0.05 −0.05%
Market cap
$6.6B
P/E
24.3×
Fwd P/E
21.3×
Dividend yield
—
F-score
5/9
Altman Z
4.25
Beneish M
−2.23
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
24.03 26.35 18.02 19.35

+8 more quarters

P/S ratio
4.16 4.64 3.18 2.91
P/FCF ratio
16.53 18.40 12.85 12.69
P/Operating CF
63.73 78.40 39.24 49.81
P/B ratio
4.95 5.51 4.05 4.12
EV/Sales
4.09 4.63 3.22 3.05
EV/EBITDA
16.53 18.23 13.33 12.20
EV/FCF
16.25 18.35 13.04 13.28
Current Ratio
3.25 3.06 2.83 2.70
Net Debt/EBITDA
0.00 (0.18) 0.68 2.08
Debt/Equity
0.42 0.44 0.47 0.52
Earnings Yield
4.16% 3.79% 5.55% 5.17%
Free Cash Flow Yield
6.05% 5.43% 7.78% 7.88%
Free Cash Flow per Share
1.45 1.38 1.96 1.21
Book value per Share
20.76 20.13 18.73 16.15
Free Cash Flow
94.93 89.87 126.90 81.39
EV/EBIT
21.95 23.84 17.17 15.13
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026